|
|
SFX by Ex Libris Inc. |
Contains information about title and source of a journal
Naslov: |
Oteseconazole: First Approved Orally Bioavailable and SelectiveCYP51 Inhibitor for the Treatment of Patients with RecurrentVulvovaginal Candidiasis |
Vir: |
|
|
|
|
List of services to meet your request
Contains list of services for current record
Basic services |
|
|
Dodatne storitve |
|
|
© 2024 SFX by Ex Libris Inc. | Politika piškotkov
CrossRef Omogočeno
|